Greater Bay Area Clinical Collaboration Platform Drives Cross-border Medical Innovation
AM730 · 1 SOURCES1 day ago3 MIN
Summary
The One Institute One Center framework has operationalized the Greater Bay Area Clinical Trial Collaboration Platform since December 2025, creating a comprehensive ecosystem that integrates Hong Kong's internationally aligned regulatory standards with the mainland's extensive clinical resources and vast patient base. Professor Zhang Wenyong, CEO of the Guangdong-Hong Kong-Macao Greater Bay Area International Clinical Trials Institute, highlighted that Hong Kong's robust institutional framework and global networks, combined with the mainland's abundant resources and industrial foundation, position the region as a key hub for international medical innovation. Multiple cross-border research collaborations have already demonstrated the synergies between Hong Kong and mainland research teams.
Key Points
- The Greater Bay Area Clinical Trial Collaboration Platform, established in December 2025, offers one-stop services including regulatory strategy consultation, research center matching, cross-border trial coordination, and patient recruitment
- Assistant Professor Zhang Yihua from HKU and Dr. Peng Qiyu from Shenzhen Bay Laboratory are jointly developing a wearable PET brain scanning system, accelerating translation from laboratory prototypes to clinical validation
- Dr. Jin Xia, CEO of IMB Biosciences Group, is conducting Phase 1 clinical trials at CUHK's Phase 1 Clinical Trial Centre at Prince of Wales Hospital, with Phase 2 multi-center trials planned across nine cities including Beijing, Tianjin, Zhengzhou, Chengdu, Chongqing, Nanjing, Guangzhou, Shenzhen, and Hong Kong
- Professor Lin Shunchao, founder of CymaBay Therapeutics, is leveraging the platform to conduct cross-border multi-center clinical trials for metastatic breast cancer and age-related macular degeneration treatments
- CARE Summit 2026 will take place at the Hong Kong Convention and Exhibition Centre on November 4-5, convening academic, medical, industry, and regulatory leaders from the Greater Bay Area, Australia, South Korea, Singapore, Malaysia, and the United Kingdom
Why It Matters
The integration of Hong Kong's internationally recognized clinical trial standards with the mainland's large-scale patient resources creates a unique environment for accelerating medical innovation. This collaboration enables faster translation of research discoveries into clinical applications, benefiting patients across the region with earlier access to cutting-edge treatments . The platform's success could establish Hong Kong as a preferred site for international pharmaceutical companies seeking to conduct multi-regional clinical trials in Asia .
The integration of Hong Kong's internationally recognized clinical trial standards with the mainland's large-scale patient resources creates a unique environment for accelerating medical innovation. This collaboration enables faster translation of research discoveries into clinical applications, benefiting patients across the region with earlier access to cutting-edge treatments . The platform's success could establish Hong Kong as a preferred site for international pharmaceutical companies seeking to conduct multi-regional clinical trials in Asia .